Literature DB >> 22351683

Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey.

Javier Pemán1, Emilia Cantón, Guillermo Quindós, Elena Eraso, Julia Alcoba, Jesús Guinea, Paloma Merino, María Teresa Ruiz-Pérez-de-Pipaon, Luisa Pérez-del-Molino, María José Linares-Sicilia, Francesc Marco, Julio García, Eva María Roselló, Elia Gómez-G-de-la-Pedrosa, Nuria Borrell, Aurelio Porras, Genoveva Yagüe.   

Abstract

OBJECTIVES: To update the knowledge of the epidemiology of fungaemia episodes in Spain, the species implicated and their in vitro antifungal susceptibilities.
METHODS: Episodes were identified prospectively over 13 months at 44 hospitals. Molecular methods were used to determine the cryptic species inside the Candida parapsilosis and Candida glabrata complexes. Susceptibility to amphotericin B, anidulafungin, caspofungin, fluconazole, flucytosine, itraconazole, micafungin, posaconazole and voriconazole was determined by a microdilution colorimetric method. New species-specific clinical breakpoints (SSCBPs) for echinocandins, fluconazole and voriconazole were applied.
RESULTS: The incidence of the 1357 fungaemia episodes evaluated was 0.92 per 1000 admissions. The incidence of Candida albicans fungaemia was the highest (0.41 episodes/1000 admissions), followed by Candida parapsilosis sensu stricto (0.22). Candida orthopsilosis was the fifth cause of fungaemia (0.02), outnumbered by Candida glabrata and Candida tropicalis. Interestingly, the incidence of fungaemia by C. parapsilosis was 11 and 74 times higher than that by C. orthopsilosis and Candida metapsilosis, respectively. Neither Candida nivariensis nor Candida bracarensis was isolated. Fungaemia was more common in non-intensive care unit settings (65.2%) and among elderly patients (46.4%), mixed fungaemia being incidental (1.5%). Overall susceptibility rates were 77.6% for itraconazole, 91.9% for fluconazole and 96.5%-99.8% for the other agents. Important resistance rates were only observed in C. glabrata for itraconazole (24.1%) and posaconazole (14.5%), and in Candida krusei for itraconazole (81.5%).
CONCLUSIONS: Fungaemia is more common in non-critical patients. C. albicans is the most common species, followed by C. parapsilosis and C. glabrata. Nearly 90% of yeasts are susceptible to all antifungal agents tested. Resistance rates change moderately when applying the new SSCBPs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22351683     DOI: 10.1093/jac/dks019

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  54 in total

1.  Comparative evaluation of BD Phoenix and vitek 2 systems for species identification of common and uncommon pathogenic yeasts.

Authors:  Brunella Posteraro; Alberto Ruggeri; Elena De Carolis; Riccardo Torelli; Antonietta Vella; Flavio De Maio; Walter Ricciardi; Patrizia Posteraro; Maurizio Sanguinetti
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

2.  Clinical and microbiological investigation of fungemia from four hospitals in China.

Authors:  Danfeng Dong; Zhen Li; Lihua Zhang; Cen Jiang; Enqiang Mao; Xuefeng Wang; Yibing Peng
Journal:  Mycopathologia       Date:  2015-02-27       Impact factor: 2.574

3.  Clinical characteristics and predictors of mortality in patients with candidemia: a six-year retrospective study.

Authors:  Xiaojiong Jia; Congya Li; Ju Cao; Xianan Wu; Liping Zhang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-07-20       Impact factor: 3.267

4.  Multidrug-resistant Trichosporon: an unusual fungal sepsis in preterm neonates.

Authors:  Sriparna Basu; Ragini Tilak; Ashok Kumar
Journal:  Pathog Glob Health       Date:  2015-06-03       Impact factor: 2.894

5.  Epidemiology of candidemia in Qatar, the Middle East: performance of MALDI-TOF MS for the identification of Candida species, species distribution, outcome, and susceptibility pattern.

Authors:  S J Taj-Aldeen; A Kolecka; R Boesten; A Alolaqi; M Almaslamani; P Chandra; J F Meis; T Boekhout
Journal:  Infection       Date:  2013-12-19       Impact factor: 3.553

6.  Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center.

Authors:  Laura Judith Marcos-Zambrano; Pilar Escribano; Carlos Sánchez; Patricia Muñoz; Emilio Bouza; Jesús Guinea
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

7.  The Etest Performed Directly on Blood Culture Bottles Is a Reliable Tool for Detection of Fluconazole-Resistant Candida albicans Isolates.

Authors:  Pilar Escribano; Laura Judith Marcos-Zambrano; Ana Gómez; Carlos Sánchez; M Carmen Martínez-Jiménez; Emilio Bouza; Jesús Guinea
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

8.  Protective effect of a novel antifungal peptide derived from human chromogranin a on the immunity of mice infected with Candida krusei.

Authors:  Ruifang Li; Lin Zhang; Huiru Zhang; Yanjie Yi; Le Wang; Liang Chen; Lan Zhang
Journal:  Exp Ther Med       Date:  2017-03-30       Impact factor: 2.447

9.  Endemic genotypes of Candida albicans causing fungemia are frequent in the hospital.

Authors:  Pilar Escribano; Marta Rodríguez-Créixems; Carlos Sánchez-Carrillo; Patricia Muñoz; Emilio Bouza; Jesús Guinea
Journal:  J Clin Microbiol       Date:  2013-04-24       Impact factor: 5.948

10.  Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011.

Authors:  Jesús Guinea; Óscar Zaragoza; Pilar Escribano; Estrella Martín-Mazuelos; Javier Pemán; Ferrán Sánchez-Reus; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.